- Home
- WGRX vs CVM Comparison
WGRX vs CVM Comparison
Compare WGRX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGRX | CVM |
|---|---|---|
| Founded | 2022 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 53.1M |
| IPO Year | 2025 | 1987 |
Fundamental Metrics
Financial Performance| Metric | WGRX | CVM |
|---|---|---|
| Price | $0.57 | $6.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 997.7K | 58.3K |
| Earning Date | 11-19-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,077,635.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 495.93 | N/A |
| 52 Week Low | $0.34 | $1.98 |
| 52 Week High | $7.04 | $32.70 |
Technical Indicators
Market Signals| Indicator | WGRX | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 42.89 |
| Support Level | $0.52 | $6.20 |
| Resistance Level | $0.64 | $6.69 |
| Average True Range (ATR) | 0.05 | 0.54 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 45.62 | 35.71 |
Price Performance
Historical ComparisonAbout WGRX Wellgistics Health Inc.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.